Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Depreciation & Amortization (CF) (2021 - 2025)

PAVmed has reported Depreciation & Amortization (CF) over the past 5 years, most recently at $18000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $18000.0 for Q4 2025, down 73.91% from a year ago — trailing twelve months through Dec 2025 was $105000.0 (down 89.06% YoY), and the annual figure for FY2025 was $105000.0, down 91.24%.
  • Depreciation & Amortization (CF) for Q4 2025 was $18000.0 at PAVmed, down from $22000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for PAVM hit a ceiling of $815000.0 in Q2 2022 and a floor of $10000.0 in Q2 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $216000.0 (2022), compared with a mean of $351263.2.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 8050.0% in 2022 and later tumbled 92.79% in 2025.
  • PAVmed's Depreciation & Amortization (CF) stood at $166000.0 in 2021, then soared by 337.35% to $726000.0 in 2022, then fell by 0.14% to $725000.0 in 2023, then plummeted by 90.48% to $69000.0 in 2024, then crashed by 73.91% to $18000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $18000.0 (Q4 2025), $22000.0 (Q3 2025), and $22000.0 (Q2 2025) per Business Quant data.